Virax Biolabs Group Stock Today
| VRAX Stock | USD 0.98 0.06 5.77% |
PerformanceVery Weak
| Odds Of DistressBelow Average
|
Virax Biolabs is trading at 0.98 as of the 1st of May 2025; that is 5.77 percent down since the beginning of the trading day. The stock's open price was 1.04. Virax Biolabs has about a 34 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 2nd of March 2025 and ending today, the 1st of May 2025. Click here to learn more.
Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom. The company has 4.34 M outstanding shares of which 258.75 K shares are at this time shorted by private and institutional investors with about 0.89 trading days to cover. More on Virax Biolabs Group
Moving together with Virax Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Virax Stock Highlights
Virax Biolabs Group (VRAX) is traded on NASDAQ Exchange in USA. It is located in BioCity Glasgow, Lanarkshire, United Kingdom, ML1 5UH and employs 17 people. Virax Biolabs is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.82 M. Virax Biolabs Group conducts business under Biotechnology sector and is part of Health Care industry. The entity has 4.34 M outstanding shares of which 258.75 K shares are at this time shorted by private and institutional investors with about 0.89 trading days to cover.
Virax Biolabs Group currently holds about 21.76 K in cash with (6.25 M) of positive cash flow from operations.
Check Virax Biolabs Probability Of Bankruptcy
Ownership AllocationVirax Biolabs Group has 6.63 % of its outstanding shares held by insiders and 6.72 % owned by institutional holders.
Check Virax Ownership Details
Virax Biolabs Group Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Virax Biolabs market risk premium is the additional return an investor will receive from holding Virax Biolabs long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.17) | |||
| Jensen Alpha | (0.54) | |||
| Total Risk Alpha | (0.14) | |||
| Treynor Ratio | (0.65) |
Virax Stock Against Markets
Virax Biolabs Corporate Management
| Tomasz George | Chief Officer | Profile | |
| Joel Yeung | Accounting Manager | Profile | |
| Nigel MSc | Chief Officer | Profile | |
| Cameron Shaw | COO Director | Profile | |
| James Wang | Head Sourcing | Profile | |
| James Foster | Chairman CEO | Profile |
Additional Tools for Virax Stock Analysis
When running Virax Biolabs' price analysis, check to measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.